← Back to feed

Ondine Biomedical Inc.

OBI · AIM · Health Care · mcap £51m today

All announcements

All RNS · 46 Key events · 36

30 Sep 26

Capital Access Window - Ondine Biomedical Inc.

COMMON SHARES OF NO PAR VALUE, FULLY PAID (CDI)
RNS 9798421 ↗
30 Sep 26

Capital Access Window

(AIM: OBI), a leader in light-activated antimicrobial therapies for the prevention and treatment of hospital infections, announces its intention to utilise AIM’s new Capital Access Window in connection with a proposed equity capital raise (the “Proposed...
RNS 9797744 ↗
30 Sep 26

2026 Interim Results & Post-Period Momentum

Ondine Biomedical Reports H1 2026 Results Following Positive Phase 3 Topline Readout and Continued Commercial Progress
RNS 9797683 ↗
29 Sep 26

Ondine and Mela Advance NHS ICU Market Access

Ondine Biomedical Leverages Mela Solutions' 90% NHS ICU Footprint to Advance Commercial Evaluation and Quantify Steriwave® Financial Impact
RNS 9795283 ↗
23 Sep 26

Steriwave Deploys in 5 Southern Ontario Hospitals

Five Southern Ontario Hospitals to Deploy Steriwave® Across Approximately 5,000 Annual Surgical Procedures
RNS 9785657 ↗
10 Sep 26

Investor Presentation of Phase 3 Topline Results

Ondine Biomedical to Present Topline Results from Phase 3 LANTERN Trial
RNS 9764382 ↗
07 Sep 26

Largest Private Mexican Network Pilots Steriwave

Hospitales Ángeles Health System Pilots Steriwave® Nasal Photodisinfection in two flagship Mexican Hospitals
RNS 9757612 ↗
04 Sep 26

Holding(s) in Company
RNS 9755159 ↗
03 Sep 26

Notification of major holdings - Pentwater
RNS 9754087 ↗
01 Sep 26

Positive Topline Results in US Phase 3 Study

Ondine Biomedical Announces Positive Topline Results from Phase 3 Pivotal LANTERN Study
RNS 9747539 ↗
30 Jul 26

Major Scottish Hospital Adopts Steriwave

UK's Largest Hip and Knee Replacement Centre Becomes First in Scotland to Adopt Steriwave® Nasal Photodisinfection
RNS 9694727 ↗
13 Jul 26

Update on US Phase 3 Pivotal Study

(AIM: OBI), a leader in light-activated antimicrobial therapies to prevent and treat hospital infections, today provides an update on its LANTERN Phase 3 pivotal study evaluating the Company's non-antibiotic nasal photodisinfection technology (branded as...
RNS 9664251 ↗
01 Jul 26

Keynote Address at 8th Annual Photodynamic Day

Ondine Biomedical Keynote Address at 8th Annual Photodynamic Day in Türkiye
RNS 9645718 ↗
30 Jun 26

Result of AGM and voting results
RNS 9645448 ↗
30 Jun 26

Leeds drops SSI 78% over Mupirocin with Steriwave

Published Leeds Study Shows Steriwave® Reduced Surgical Site Infections by 78% versus standard of care using Mupirocin in High Risk Endoscopic Endonasal Skull-Base Surgery
RNS 9643058 ↗
22 Jun 26

Update on US Phase 3 Pivotal Study

(AIM: OBI), a leader in light-activated antimicrobial therapies to prevent and treat hospital infections, today provides an update on its LANTERN Phase 3 pivotal study evaluating the Company's non-antibiotic nasal photodisinfection technology (branded as...
RNS 9628754 ↗
18 Jun 26

Leeds Drops SSIs by 78.5% in Complex Brain Surgery

Nasal Photodisinfection Reduces Surgical Infections in Complex Brain Surgery by 78.5% Compared to Nasal Antibiotics at Leeds Teaching Hospitals
RNS 9624122 ↗
08 Jun 26

Grant of Options and RSUs, and Issue of Warrants
RNS 9607461 ↗
04 Jun 26

Notice of AGM
RNS 9600721 ↗
04 Jun 26

2025 Full Year Results and Annual Report

Near-term Phase 3 pivotal study read out; growing international real-world evidence and commercial traction
RNS 9600669 ↗
28 May 26

Notice of Results and Investor Presentation
RNS 9588705 ↗
26 May 26

Steriwave ICU Study Outcomes Presented at CSRT2026

SMURF Feasibility Study of Nasal Photodisinfection Presented at National Respiratory Conference
RNS 9585683 ↗
06 May 26

Notification of major holdings - hInsight-NX, LLC
RNS 9554727 ↗
06 May 26

Notification of major holdings - Carolyn Cross
RNS 9554714 ↗
05 May 26

Notification of major holdings - Pentwater
RNS 9553355 ↗
30 Apr 26

Ondine Presented Steriwave Data at IPC 2026

Ondine Biomedical Presented Steriwave Data at Recent Infection Prevention and Control Conference (IPC 2026)
RNS 9546596 ↗
29 Apr 26

Result of Fundraise & TVR

All references to C$ in this announcement ("Announcement") are to Canadian Dollars.
RNS 9542932 ↗
28 Apr 26

Proposed c.£5 million (C$9.23 million) Fundraise

THIS ANNOUNCEMENT SHOULD BE READ IN ITS ENTIRETY.
RNS 9542619 ↗
27 Apr 26

ICU Study to be Presented at 2026 CACCN Conference

Steriwave ICU Study Findings Selected for Oral Presentation at National Canadian Critical Care Nursing Conference
RNS 9538217 ↗
23 Apr 26

Marked Reduction in SSIs at Ottawa Heart Institute

University of Ottawa Heart Institute Reduces Surgical Site Infections Following Implementation of Steriwave Nasal Photodisinfection
RNS 9533792 ↗
22 Apr 26

Two Abstracts Accepted at World Congress

Ondine Biomedical Announces Selection of Two Abstracts for Presentation at the 2026 World Congress on Infectious Diseases
RNS 9531562 ↗
14 Apr 26

Steriwave ICU Study Shows 39.5% Pneumonia Drop

Pioneering research from Royal Columbian Hospital Foundation shows a significant decrease in pneumonia rates and establishes a new benchmark for ICU infection prevention.
RNS 9518091 ↗
13 Apr 26

Business Update

· Clinical Milestones: Completed patient enrolment in the pivotal LANTERN Phase 3 U.S. trial, with results expected in Spring 2026.
RNS 9515719 ↗
08 Apr 26

ICU Study Accepted for Publication

Ondine Biomedical and Royal Columbian Hospital Foundation Announce Major Research Milestone: First-of-its-Kind ICU Study Accepted by 'Journal of Critical Care'
RNS 9509423 ↗
10 Mar 26

Ondine Provides Update on US Phase 3 Pivotal Study

Ondine Provides Update on US Phase 3 Pivotal Study
RNS 9465871 ↗
03 Mar 26

Holding(s) in Company
RNS 9454721 ↗
25 Feb 26

Share Issuance for ICU Study Submission

Milestone-based Share Issuance Following Submission of Steriwave® ICU Study Results for Publication
RNS 9445508 ↗
06 Feb 26

Ondine and Mid Yorks Win National Award

Excellence in Healthcare Partnership Award recognises proven collaboration delivering significant SSI reductions and supporting NHS priorities
RNS 9413666 ↗
02 Feb 26

Steriwave Up for 2025 “Product of the Year” Award

Steriwave Up for 2025 "Product of the Year" Award
RNS 9399928 ↗
27 Jan 26

Expanding Steriwave Use Across Vancouver Island

Island Health's New Regional Powerhouse, Cowichan District Hospital, Adopts Steriwave to Lead Vancouver Island in Surgical Innovation
RNS 9388104 ↗
22 Jan 26

Steriwave Expands into ENT Surgery in Spain

(AIM: OBI), a leader in light-activated antimicrobial therapies, is pleased to announce the deployment of its Steriwave® nasal photodisinfection technology into a leading ear, nose and throat (ENT) specialist group operating surgical centres in Madrid and Málaga.
RNS 9375855 ↗
13 Jan 26

New Independent Study Supports Photodisinfection

Ondine Biomedical Provides Biological Context for Nasal Decolonization Strategies Following Landmark Nasal Microbiome Study
RNS 9349075 ↗
23 Dec 25

Finalist for 2nd National Award for SSI reduction

Finalist for 2nd National Award for SSI reduction
RNS 9314250 ↗
22 Dec 25

First German Hospital Pilots Steriwave

Ondine Biomedical Partners with LMU University Hospital Munich
RNS 9311379 ↗
16 Dec 25

Ondine shortlisted for HSJ Partnership Award

HSJ Partnership Award Finalists: Ondine Biomedical and Mid Yorkshire Teaching NHS Trust for Cutting Post-surgical Infection Rates
RNS 9298704 ↗
27 Oct 25

Topline Results Significant in Steriwave ICU Study

Steriwave Shows Significant Sustained ICU Pathogen Reduction in Royal Columbian Hospital Study Reinforcing Universal Nasal Decolonisation for Infection Control
RNS 9195072 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.